VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • March 19th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2024, by and between AstraZeneca AB, a public company with limited liability (Aktiebolag), incorporated under the laws of Sweden (“Parent”), and the undersigned holder (the “Shareholder”) of common shares of Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Corporation”). Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Arrangement Agreement, dated as of March 18, 2024, by and among Parent, 15863210 Canada Inc., a corporation formed under the federal laws of Canada and a wholly owned subsidiary of Parent (“Purchaser”), and the Corporation (as such agreement may be subsequently amended or modified, the “Arrangement Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Arrangement Agreement.
ASTRAZENECA AB — and — 15863210 CANADA INC. — and — FUSION PHARMACEUTICALS INC. ARRANGEMENT AGREEMENT March 18, 2024Arrangement Agreement • March 19th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
ASTRAZENECA AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden, having its official seat in Södertälje, Sweden, its registered office address at 151 85 Södertälje, Sweden and registered with the trade register of the Swedish Companies Registration Office under number 556011-7482 (the Parent)
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 19th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) to that certain Employment Agreement, dated as of December 18, 2023 (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of March 18, 2024 (the “Effective Date”).
